ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

06 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

05 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

27 Feb 2025 08:00:01 By Nasdaq GlobeNewswire

ALX Oncology to Host Virtual R&D Day on March 5, 2025

18 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

23 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

22 Jan 2025 16:01:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

22 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

21 Jan 2025 17:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

18 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

12 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

10 Dec 2024 09:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

14 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

07 Nov 2024 16:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces November Investor Conference Participation

04 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

01 Nov 2024 17:30:00 By Nasdaq GlobeNewswire

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

09 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

04 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

08 Aug 2024 16:05:00 By Nasdaq GlobeNewswire